Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham

Executive Summary

Jerry Karabelas becomes VP-marketing of the company's U.S. prescription drug business effective June 27. Karabelas originally joined SmithKline in 1982, eventually becoming a group VP for gastrointestinal products. He left the firm in December 1989 to become CEO of Cellular Transplants Inc., a Providence, Rhode Island-based biotech firm. In his new position at SmithKline Beecham, Karabelas will replace Roger Ross, a 25-year SmithKline veteran who has decided to leave the company. The VP-marketing position currently reports to Fred Kyle, who heads U.S. pharmaceutical operations. However, the company is seeking a replacement for Kyle, who was recently given overall responsibility for worldwide manufacturing.

You may also be interested in...



The Top Five (Non-COVID) Pharma Stories Of 2020

The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.

China Rings In New Year With Major Deals, Record IPOs And Trends To Watch

From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel